---
title: "Vigil Neuroscience | 10-Q: FY2025 Q2 EPS Misses Estimate at USD -0.56"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/251617479.md"
datetime: "2025-08-05T10:47:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/251617479.md)
  - [en](https://longbridge.com/en/news/251617479.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/251617479.md)
generator: "portal-rs"
---

# Vigil Neuroscience | 10-Q: FY2025 Q2 EPS Misses Estimate at USD -0.56

EPS: As of FY2025 Q2, the actual value is USD -0.56, missing the estimate of USD -0.4243.

EBIT: As of FY2025 Q2, the actual value is USD -26.66 M, missing the estimate of USD -24.23 M.

### Segment Revenue

-   **Research and Development**: $17.4 million for the three months ended June 30, 2025, compared to $15.5 million for the same period in 2024, and $33.9 million for the six months ended June 30, 2025, compared to $29.9 million for the same period in 2024.
-   **General and Administrative**: $10.1 million for the three months ended June 30, 2025, compared to $6.9 million for the same period in 2024, and $17.0 million for the six months ended June 30, 2025, compared to $14.0 million for the same period in 2024.

### Operational Metrics

-   **Net Loss**: $26.7 million for the three months ended June 30, 2025, compared to $21.2 million for the same period in 2024, and $49.1 million for the six months ended June 30, 2025, compared to $41.2 million for the same period in 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: - $44.4 million for the six months ended June 30, 2025, compared to - $37.4 million for the same period in 2024.
-   **Net Cash Provided by Investing Activities**: $33.0 million for the six months ended June 30, 2025, compared to $17.5 million for the same period in 2024.
-   **Net Cash Provided by Financing Activities**: $13.5 million for the six months ended June 30, 2025, compared to $5.2 million for the same period in 2024.

### Unique Metrics

-   **Cash, Cash Equivalents, and Marketable Securities**: $67.0 million as of June 30, 2025.

### Future Outlook and Strategy

-   **Core Business Focus**: Vigil Neuroscience, Inc. is focused on developing VG-3927, a small molecule TREM2 agonist for Alzheimer’s disease, and has entered into a merger agreement with Sanofi, which is expected to close in the third quarter of 2025.
-   **Non-Core Business**: The rights to iluzanebart will be returned to Amgen Inc. as part of the merger agreement with Sanofi.

### Related Stocks

- [VIGL.US](https://longbridge.com/en/quote/VIGL.US.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**